News und Analysen
EQS-Adhoc: Eckert & Ziegler Receives Green Light for Phase III Study with PENTIXAFOR
EQS-Adhoc: Eckert & Ziegler Receives Green Light for Phase III Study with PENTIXAFOR
EQS-News: Eckert & Ziegler: Nine-Month Figures Show Strong Sales Growth
EQS-News: Eckert & Ziegler: Nine-Month Figures Show Strong Sales Growth
EQS-News: First CNS Lymphoma Patient Imaged with PentixaFor in Phase 2 Trial
EQS-News: First CNS Lymphoma Patient Imaged with PentixaFor in Phase 2 Trial
TIAP and Evotec Expand LAB150 BRIDGE Partnership to Include Amgen
Toronto Innovation Acceleration Partners (“TIAP”) and Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) today announced that the two companies have expanded
EQS-News: Eckert & Ziegler and Alpha-9 Sign Actinium-225 (Ac-225) Reservation Agreement
EQS-News: Eckert & Ziegler and Alpha-9 Sign Actinium-225 (Ac-225) Reservation Agreement
EQS-News: Eckert & Ziegler to Build Production Line for NorthStar Medical Radioisotopes’ Dedicated Actinium-225 Production Facility
EQS-News: Eckert & Ziegler to Build Production Line for NorthStar Medical Radioisotopes’ Dedicated Actinium-225 Production Facility
DGAP-News: Eckert & Ziegler with Successful First Half of 2022
DGAP-News: Eckert & Ziegler with Successful First Half of 2022
DGAP-News: Eckert & Ziegler Affiliate to Receive Multi-Million Euro Grant from the European Defense Fund for Development of Medical Countermeasures
DGAP-News: Eckert & Ziegler Affiliate to Receive Multi-Million Euro Grant from the European Defense Fund for Development of Medical Countermeasures
DGAP-Adhoc: Eckert & Ziegler: Strong Growth in Revenues and Earnings in 2nd Quarter
DGAP-Adhoc: Eckert & Ziegler: Strong Growth in Revenues and Earnings in 2nd Quarter
DGAP-News: Eckert & Ziegler Affiliate Receives Further NIAID Funding for Clinical Development
DGAP-News: Eckert & Ziegler Affiliate Receives Further NIAID Funding for Clinical Development
DGAP-News: Eckert & Ziegler and PRECIRIX Sign Agreement on Priority Supply of the Therapeutic Radioisotope Actinium-225 (Ac-225)
DGAP-News: Eckert & Ziegler and PRECIRIX Sign Agreement on Priority Supply of the Therapeutic Radioisotope Actinium-225 (Ac-225)
DGAP-News: Eckert & Ziegler Becomes Contract Manufacturer for Clinical Development Candidates Based on Lutetium-177 and Actinium-225
DGAP-News: Eckert & Ziegler Becomes Contract Manufacturer for Clinical Development Candidates Based on Lutetium-177 and Actinium-225
DGAP-Adhoc: Eckert & Ziegler Lowers 2022 Profit Guidance to 27 mm EUR
DGAP-Adhoc: Eckert & Ziegler Lowers 2022 Profit Guidance to 27 mm EUR
DGAP-News: Eckert & Ziegler with Sales Growth in the First Quarter of 2022
DGAP-News: Eckert & Ziegler with Sales Growth in the First Quarter of 2022
DGAP-News: Eckert & Ziegler Cooperates with Czech Research Center UJF to Produce Pharmaceutical Alpha Radioisotopes
DGAP-News: Eckert & Ziegler Cooperates with Czech Research Center UJF to Produce Pharmaceutical Alpha Radioisotopes
DGAP-News: Evotec SE fiscal year 2021 results: 'Setting the Pace' on the data-driven R&D Autobahn to Cures
DGAP-News: Evotec SE fiscal year 2021 results: 'Setting the Pace' on the data-driven R&D Autobahn to Cures
DGAP-News: Evotec SE veröffentlicht Ergebnisse des Geschäftsjahres 2021: 'Setting the Pace' auf der 'data-driven R&D Autobahn to Cures'
DGAP-News: Evotec SE veröffentlicht Ergebnisse des Geschäftsjahres 2021: 'Setting the Pace' auf der 'data-driven R&D Autobahn to Cures'
DGAP-News: Evotec erreicht Programmauswahl in Neurologie-Kooperation mit Bristol Myers Squibb
DGAP-News: Evotec erreicht Programmauswahl in Neurologie-Kooperation mit Bristol Myers Squibb
DGAP-News: Evotec achieves programme designation in neuroscience collaboration with Bristol Myers Squibb
DGAP-News: Evotec achieves programme designation in neuroscience collaboration with Bristol Myers Squibb
DGAP-HV: MorphoSys AG: Bekanntmachung der Einberufung zur Hauptversammlung am 18.05.2022 in Planegg mit dem Ziel der europaweiten Verbreitung gemäß §121 AktG
DGAP-HV: MorphoSys AG: Bekanntmachung der Einberufung zur Hauptversammlung am 18.05.2022 in Planegg mit dem Ziel der europaweiten Verbreitung gemäß §121 AktG
DGAP-News: Evotec SE to announce results for fiscal year 2021 on 12 April 2022
DGAP-News: Evotec SE to announce results for fiscal year 2021 on 12 April 2022
DGAP-News: Evotec SE: Bekanntgabe der Ergebnisse für das Geschäftsjahr 2021 am 12. April 2022
DGAP-News: Evotec SE: Bekanntgabe der Ergebnisse für das Geschäftsjahr 2021 am 12. April 2022
DGAP-News: MorphoSys and Incyte Announce Swissmedic Temporary Approval of Minjuvi(R) (tafasitamab) in Combination with Lenalidomide for the Treatment of Adults with r/r DLBCL
DGAP-News: MorphoSys and Incyte Announce Swissmedic Temporary Approval of Minjuvi(R) (tafasitamab) in Combination with Lenalidomide for the Treatment of Adults with r/r DLBCL
DGAP-News: MorphoSys und Incyte geben vorläufige Swissmedic-Zulassung von Minjuvi(R) (Tafasitamab) in Kombination mit Lenalidomid zur Behandlung von erwachsenen Patienten mit R/R DLBCL bekannt
DGAP-News: MorphoSys und Incyte geben vorläufige Swissmedic-Zulassung von Minjuvi(R) (Tafasitamab) in Kombination mit Lenalidomid zur Behandlung von erwachsenen Patienten mit R/R DLBCL bekannt
DGAP-News: Evotec erhält 3 Mio. €-Meilenstein für Bayers Start einer klinischen Phase-II-Studie mit DNP-Programm
DGAP-News: Evotec erhält 3 Mio. €-Meilenstein für Bayers Start einer klinischen Phase-II-Studie mit DNP-Programm